ClinicalTrials.gg
CompletedNCT04594213ULTRA IUpdated May 8, 2024Results posted

Safety and Efficacy Study of the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines and Lateral Canthal Lines) in Subjects With Moderate to Severe Upper Facial Lines

A Phase 3 interventional study of NT 201 and Placebo in Moderate to Severe Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines, and Lateral Canthal Lines), sponsored by Merz North America, Inc.. Completed at 12 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-08.

Sponsored by Merz North America, Inc. (part of Merz Pharma) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
362
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to investigate the safety and efficacy of NT 201 (active ingredient: Botulinum (neuro)toxin type A, free from complexing proteins) in the combined treatment of wrinkles in the upper face (Upper Facial Lines [UFL]): Horizontal Forehead Lines [HFL], Glabellar Frown Lines [GFL], and Lateral Canthal Lines [LCL]). It is a prospective, randomized, double-blind, placebo-controlled, multicenter study with a placebo-control main period (MP) followed by an open-label extension (OLEX) period.

02

Conditions studied

  • Moderate to Severe Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines, and Lateral Canthal Lines)
03

In context

Lead sponsor

Merz North America, Inc. is the lead sponsor of 53 studies on the registry; 2 are open to participants now.

Of its 20 completed or terminated interventional studies of FDA-regulated products, 19 (95%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Outpatients (male or female) 18 years of age or older.
  • Horizontal forehead lines (HFL), glabellar frown lines (GFL), and symmetrical lateral canthal lines (LCL) of moderate to severe intensity at maximum contraction as assessed by the investigator and subject according to Merz Aesthetics Scales (MAS).

Exclusion criteria

Exclusion Criteria:

  • Previous treatment with botulinum neurotoxin (BoNT) of any serotype in the face within the last 12 months before injection.
  • Any facial cosmetic procedure within the last 12 months before baseline injection.
  • Previous treatment with any biodegradable filler in the face within the last 12 months before injection.
  • Any previous insertion of permanent material in the face (regardless of the time between previous treatment and this study).
  • Any medical condition that may put the subject at increased risk with exposure to NT201.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
362 participants (actual)

Study arms

  • Placebo comparator
    Main Period: Placebo (Group P)

    Subjects will receive placebo injection in all three UFL (GFL, HFL and LCL) on Day 1 of main period.

    Drug: Placebo

  • Experimental
    Main Period: NT 201 (Group U)

    Subjects will receive a total of 64 Units (U) of NT 201: 20 U of NT 201 injection both in the GFL area and in the HFL area, and 24 U of NT 201 injection in the LCL area (12 U per side) on Day 1 of main period.

    Drug: NT 201

  • Experimental
    Main Period: NT 201 and Placebo (Group G and H)

    Subjects will receive a total of 40 U of NT 201: 20 U of NT 201 injection both in the GFL and HFL area, and placebo injection in the LCL area on Day 1 of main period.

    Drug: NT 201 · Drug: Placebo

  • Experimental
    OLEX: NT 201 (Main Period: Group P)

    Subjects will receive a total of 64 U of NT 201: 20 U of NT 201 injection both in the GFL and in the HFL area, and 24 U of NT 201 injection in the LCL area (12 U per side) on Day 1 (Visit 8) and Visit 13 of OLEX period.

    Drug: NT 201

  • Experimental
    OLEX: NT 201 (Main Period: Group U)

    Subjects will receive a total of 64 U of NT 201: 20 U of NT 201 injection both in the GFL and in the HFL area, and 24 U of NT 201 injection in the LCL area (12 U per side) on Day 1 (Visit 8) and Visit 13 of OLEX period.

    Drug: NT 201

  • Experimental
    OLEX: NT 201 (Main Period: Group G and H)

    Subjects will receive a total of 64 U of NT 201: 20 U of NT 201 injection both in the GFL and in the HFL area, and 24 U of NT 201 injection in the LCL area (12 U per side) on Day 1 (Visit 8) and Visit 13 of OLEX period.

    Drug: NT 201

Interventions

  • DrugNT 201

    Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% NaCl.

    Also known as: IncobotulinumtoxinA, Xeomin, Botulinum toxin type A (150 kiloDalton), free from complexing protein

  • DrugPlacebo

    Solution for injection prepared by reconstitution of powder with percent (%) Sodium Chloride (NaCl).

06

What researchers measure

Primary outcomes

  1. Main Period: Percentage of Glabellar Frown Line (GFL) Responders at Day 30

    The Merz aesthetics scales (MAS) are 5-point scales used to identify responders in a clinical context. They are validated photograph-based outcome instruments designed specifically for assessment of each upper facial area. GFL-response was defined as a score of 0 (no) or 1 (mild) and at least two-grade improvement from baseline to Day 30 of main period on MAS for GFL at maximum contraction as assessed by both the investigator and the subject. The MAS for GFL ranged as 0 to 4 where 0 is "No glabellar lines", 1 is "Mild glabellar lines", 2 is "Moderate glabellar lines", 3 is "Severe glabellar lines" and 4 is "Very severe glabellar lines".

    Time frame: Day 30

  2. Main Period: Percentage of Horizontal Forehead Lines (HFL) Responders at Day 30

    The MAS are 5-point scales used to identify responders in a clinical context. They are validated photograph-based outcome instruments designed specifically for assessment of each upper facial area. HFL-response was defined as a score of 0 (no) or 1 (mild) and at least two-grade improvement from baseline to Day 30 of main period on MAS for HFL at maximum contraction as assessed by both the investigator and the subject. The MAS for HFL ranged as 0 to 4 where 0 is "No lines", 1 is "Mild lines", 2 is "Moderate lines", 3 is "Severe lines" and 4 is "Very severe lines".

    Time frame: Day 30

  3. Main Period: Percentage of Lateral Canthal Lines (LCL) Responders at Day 30

    The MAS are 5-point scales used to identify responders in a clinical context. They are validated photograph-based outcome instruments designed specifically for assessment of each upper facial area. LCL-response was defined as a score of 0 (no) or 1 (mild) and at least two-grade improvement from baseline to Day 30 of main period on MAS for both left and right LCL at maximum contraction as assessed by both the investigator and the subject. The MAS for LCL ranged as 0 to 4 where 0 is "No lines", 1 is "Mild lines", 2 is "Moderate lines", 3 is "Severe lines" and 4 is "Very severe lines".

    Time frame: Day 30

Secondary outcomes

  1. Main Period: Percentage of Subjects With a Score of 0 (no) or 1 (Mild) on MAS for GFL at Maximum Contraction as Assessed by the Investigator at Day 30

    The MAS are 5-point scales used to identify responders in a clinical context. They are validated photograph-based outcome instruments designed specifically for assessment of each upper facial area. The MAS for GFL ranged as 0 to 4 where 0 is "No glabellar lines", 1 is "Mild glabellar lines", 2 is "Moderate glabellar lines", 3 is "Severe glabellar lines" and 4 is "Very severe glabellar lines".

    Time frame: Day 30

  2. Main Period: Percentage of Subjects With a Score of 0 (no) or 1 (Mild) on MAS for HFL at Maximum Contraction as Assessed by the Investigator at Day 30

    The MAS are 5-point scales used to identify responders in a clinical context. They are validated photograph-based outcome instruments designed specifically for assessment of each upper facial area. The MAS for HFL ranged as 0 to 4 where 0 is "No lines", 1 is "Mild lines", 2 is "Moderate lines", 3 is "Severe lines" and 4 is "Very severe lines".

    Time frame: Day 30

  3. Main Period: Percentage of Subjects With a Score of 0 (no) or 1 (Mild) on MAS for Both Left and Right LCL at Maximum Contraction as Assessed by the Investigator at Day 30

    The MAS are 5-point scales used to identify responders in a clinical context. They are validated photograph-based outcome instruments designed specifically for assessment of each upper facial area. The MAS for LCL ranged as 0 to 4 where 0 is "No lines", 1 is "Mild lines", 2 is "Moderate lines", 3 is "Severe lines" and 4 is "Very severe lines".

    Time frame: Day 30

  4. Main Period: Percentage of Subjects With a Score of 0 (no) or 1 (Mild) on MAS for GFL at Maximum Contraction as Assessed by the Subject at Day 30

    The MAS are 5-point scales used to identify responders in a clinical context. They are validated photograph-based outcome instruments designed specifically for assessment of each upper facial area. The MAS for GFL ranged as 0 to 4 where 0 is "No glabellar lines", 1 is "Mild glabellar lines", 2 is "Moderate glabellar lines", 3 is "Severe glabellar lines" and 4 is "Very severe glabellar lines".

    Time frame: Day 30

  5. Main Period: Percentage of Subjects With a Score of 0 (no) or 1 (Mild) on MAS for HFL at Maximum Contraction as Assessed by the Subject at Day 30

    The MAS are 5-point scales used to identify responders in a clinical context. They are validated photograph-based outcome instruments designed specifically for assessment of each upper facial area. The MAS for HFL ranged as 0 to 4 where 0 is "No lines", 1 is "Mild lines", 2 is "Moderate lines", 3 is "Severe lines" and 4 is "Very severe lines".

    Time frame: Day 30

  6. Main Period: Percentage of Subjects With a Score of 0 (no) or 1 (Mild) on MAS for Both Left and Right LCL at Maximum Contraction as Assessed by the Subject at Day 30

    The MAS are 5-point scales used to identify responders in a clinical context. They are validated photograph-based outcome instruments designed specifically for assessment of each upper facial area. The MAS for LCL ranged as 0 to 4 where 0 is "No lines", 1 is "Mild lines", 2 is "Moderate lines", 3 is "Severe lines" and 4 is "Very severe lines".

    Time frame: Day 30

  7. Main Period: Global Aesthetic Improvement Scale (GAIS) at Day 30 as Assessed by the Subjects

    The GAIS is a 7-point Likert scale capturing the global aesthetic improvement ranging from +3 (very much improved); +2 (much improved); +1 (improved); 0 (no change); -1 (worse); -2 (much worse); -3 (very much worse), as assessed by the subject. GAIS as assessed by the subject at Day 30 was analyzed using an analysis of covariance (ANCOVA) model.

    Time frame: Day 30

  8. Main Period: Percentage of Subjects With at Least One-grade Improvement From Baseline to Day 30 on MAS for GFL at Maximum Contraction as Assessed by the Investigator

    The MAS are 5-point scales used to identify responders in a clinical context. They are validated photograph-based outcome instruments designed specifically for assessment of each upper facial area. The MAS for GFL ranged as 0 to 4 where 0 is "No glabellar lines", 1 is "Mild glabellar lines", 2 is "Moderate glabellar lines", 3 is "Severe glabellar lines" and 4 is "Very severe glabellar lines".

    Time frame: Day 30

  9. Main Period: Percentage of Subjects With at Least One-grade Improvement From Baseline to Day 30 on MAS for HFL at Maximum Contraction as Assessed by the Investigator

    The MAS are 5-point scales used to identify responders in a clinical context. They are validated photograph-based outcome instruments designed specifically for assessment of each upper facial area. The MAS for HFL ranged as 0 to 4 where 0 is "No lines", 1 is "Mild lines", 2 is "Moderate lines", 3 is "Severe lines" and 4 is "Very severe lines".

    Time frame: Day 30

  10. Main Period: Percentage of Subjects With at Least One-grade Improvement From Baseline to Day 30 on MAS for Both Left and Right LCL at Maximum Contraction as Assessed by the Investigator

    The MAS are 5-point scales used to identify responders in a clinical context. They are validated photograph-based outcome instruments designed specifically for assessment of each upper facial area. The MAS for LCL ranged as 0 to 4 where 0 is "No lines", 1 is "Mild lines", 2 is "Moderate lines", 3 is "Severe lines" and 4 is "Very severe lines".

    Time frame: Day 30

  11. Main Period: Global Aesthetic Improvement Scale (GAIS) at Day 30 as Assessed by the Investigator

    The GAIS is a 7-point Likert scale capturing the global aesthetic improvement ranging from +3 (very much improved); +2 (much improved); +1 (improved); 0 (no change); -1 (worse); -2 (much worse); -3 (very much worse), as assessed by the investigator. GAIS as assessed by the investigator at Day 30 was analyzed using an ANCOVA model.

    Time frame: Day 30

  12. Main Period: Number of Subjects With Related Treatment-Emergent Adverse Events (TEAEs)

    TEAEs during the Main Period are defined as adverse events (AEs) with onset or worsening on or after date and time of first dose of study treatment and before date and time of first administration of study treatment in the OLEX period or the final study visit, if subject was not treated in the OLEX period. An AE is considered to be related if a causal relationship between study treatment and the AE is at least reasonably possible.

    Time frame: Up to 22 Weeks

  13. OLEX Period: Number of Subjects With Related TEAEs

    TEAEs of the OLEX period are defined as AEs with onset or worsening on or after date and time of first dose of study treatment in the OLEX period up to and including the final study visit. An AE is considered to be related if a causal relationship between study treatment and the AE is at least reasonably possible.

    Time frame: Up to 39 Weeks

07

Results

Posted May 8, 2024

Participant flow

Subjects were recruited at 12 investigational sites in the United States.

Main Period (Up to 22 Weeks)
Participant flow — Main Period (Up to 22 Weeks)
MilestoneMain Period: Placebo (Group P)Main Period: NT 201 (Group U)Main Period: NT 201 and Placebo (Group G and H)OLEX: NT 201 (Main Period: Group P)OLEX: NT 201 (Main Period: Group U)OLEX: NT 201 (Main Period: Group G and H)
Started9117992000
Completed8817290000
Not completed372000
Withdrew: Withdrawal by subject261000
Withdrew: Physician decision010000
Withdrew: Lost to follow-up101000
OLEX Period (Up to 39 Weeks)
Participant flow — OLEX Period (Up to 39 Weeks)
MilestoneMain Period: Placebo (Group P)Main Period: NT 201 (Group U)Main Period: NT 201 and Placebo (Group G and H)OLEX: NT 201 (Main Period: Group P)OLEX: NT 201 (Main Period: Group U)OLEX: NT 201 (Main Period: Group G and H)
Started0008614473
Completed0006610060
Not completed000204413
Withdrew: Adverse event000020
Withdrew: Lost to follow-up000462
Withdrew: Pregnancy000001
Withdrew: Other eligibility criteria for re-injection not met000100
Withdrew: Protocol violation000100
Withdrew: Withdrawal by subject0006114
Withdrew: No need for re-injection0007225
Withdrew: Other000131

Outcome measures

PrimaryMain Period: Percentage of Glabellar Frown Line (GFL) Responders at Day 30

The Merz aesthetics scales (MAS) are 5-point scales used to identify responders in a clinical context. They are validated photograph-based outcome instruments designed specifically for assessment of each upper facial area. GFL-response was defined as a score of 0 (no) or 1 (mild) and at least two-grade improvement from baseline to Day 30 of main period on MAS for GFL at maximum contraction as assessed by both the investigator and the subject. The MAS for GFL ranged as 0 to 4 where 0 is "No glabellar lines", 1 is "Mild glabellar lines", 2 is "Moderate glabellar lines", 3 is "Severe glabellar lines" and 4 is "Very severe glabellar lines".

Time frame:
Day 30
Reported as:
Number · percentage of subjects
Main Period: Percentage of Glabellar Frown Line (GFL) Responders at Day 30
percentage of subjectsMain Period: Placebo (Group P)Main Period: NT 201 (Group U)
Main Period: Percentage of Glabellar Frown Line (GFL) Responders at Day 30052.3
Statistical analysis
  • Main Period: Placebo (Group P) vs Main Period: NT 201 (Group U) · Mantel Haenszel · p = <0.0001
PrimaryMain Period: Percentage of Horizontal Forehead Lines (HFL) Responders at Day 30

The MAS are 5-point scales used to identify responders in a clinical context. They are validated photograph-based outcome instruments designed specifically for assessment of each upper facial area. HFL-response was defined as a score of 0 (no) or 1 (mild) and at least two-grade improvement from baseline to Day 30 of main period on MAS for HFL at maximum contraction as assessed by both the investigator and the subject. The MAS for HFL ranged as 0 to 4 where 0 is "No lines", 1 is "Mild lines", 2 is "Moderate lines", 3 is "Severe lines" and 4 is "Very severe lines".

Time frame:
Day 30
Reported as:
Number · percentage of subjects
Main Period: Percentage of Horizontal Forehead Lines (HFL) Responders at Day 30
percentage of subjectsMain Period: Placebo (Group P)Main Period: NT 201 (Group U)
Main Period: Percentage of Horizontal Forehead Lines (HFL) Responders at Day 30066.5
Statistical analysis
  • Main Period: Placebo (Group P) vs Main Period: NT 201 (Group U) · Mantel Haenszel · p = <0.0001
PrimaryMain Period: Percentage of Lateral Canthal Lines (LCL) Responders at Day 30

The MAS are 5-point scales used to identify responders in a clinical context. They are validated photograph-based outcome instruments designed specifically for assessment of each upper facial area. LCL-response was defined as a score of 0 (no) or 1 (mild) and at least two-grade improvement from baseline to Day 30 of main period on MAS for both left and right LCL at maximum contraction as assessed by both the investigator and the subject. The MAS for LCL ranged as 0 to 4 where 0 is "No lines", 1 is "Mild lines", 2 is "Moderate lines", 3 is "Severe lines" and 4 is "Very severe lines".

Time frame:
Day 30
Reported as:
Number · percentage of subjects
Main Period: Percentage of Lateral Canthal Lines (LCL) Responders at Day 30
percentage of subjectsMain Period: Placebo (Group P)Main Period: NT 201 (Group U)
Main Period: Percentage of Lateral Canthal Lines (LCL) Responders at Day 30051.7
Statistical analysis
  • Main Period: Placebo (Group P) vs Main Period: NT 201 (Group U) · Mantel Haenszel · p = <0.0001
SecondaryMain Period: Percentage of Subjects With a Score of 0 (no) or 1 (Mild) on MAS for GFL at Maximum Contraction as Assessed by the Investigator at Day 30

The MAS are 5-point scales used to identify responders in a clinical context. They are validated photograph-based outcome instruments designed specifically for assessment of each upper facial area. The MAS for GFL ranged as 0 to 4 where 0 is "No glabellar lines", 1 is "Mild glabellar lines", 2 is "Moderate glabellar lines", 3 is "Severe glabellar lines" and 4 is "Very severe glabellar lines".

Time frame:
Day 30
Reported as:
Number · percentage of subjects
Main Period: Percentage of Subjects With a Score of 0 (no) or 1 (Mild) on MAS for GFL at Maximum Contraction as Assessed by the Investigator at Day 30
percentage of subjectsMain Period: Placebo (Group P)Main Period: NT 201 (Group U)
Main Period: Percentage of Subjects With a Score of 0 (no) or 1 (Mild) on MAS for GFL at Maximum Contraction as Assessed by the Investigator at Day 30088.6
Statistical analysis
  • Main Period: Placebo (Group P) vs Main Period: NT 201 (Group U) · Mantel Haenszel · p = <0.0001
SecondaryMain Period: Percentage of Subjects With a Score of 0 (no) or 1 (Mild) on MAS for HFL at Maximum Contraction as Assessed by the Investigator at Day 30

The MAS are 5-point scales used to identify responders in a clinical context. They are validated photograph-based outcome instruments designed specifically for assessment of each upper facial area. The MAS for HFL ranged as 0 to 4 where 0 is "No lines", 1 is "Mild lines", 2 is "Moderate lines", 3 is "Severe lines" and 4 is "Very severe lines".

Time frame:
Day 30
Reported as:
Number · percentage of subjects
Main Period: Percentage of Subjects With a Score of 0 (no) or 1 (Mild) on MAS for HFL at Maximum Contraction as Assessed by the Investigator at Day 30
percentage of subjectsMain Period: Placebo (Group P)Main Period: NT 201 (Group U)
Main Period: Percentage of Subjects With a Score of 0 (no) or 1 (Mild) on MAS for HFL at Maximum Contraction as Assessed by the Investigator at Day 30092.0
Statistical analysis
  • Main Period: Placebo (Group P) vs Main Period: NT 201 (Group U) · Mantel Haenszel · p = <0.0001
SecondaryMain Period: Percentage of Subjects With a Score of 0 (no) or 1 (Mild) on MAS for Both Left and Right LCL at Maximum Contraction as Assessed by the Investigator at Day 30

The MAS are 5-point scales used to identify responders in a clinical context. They are validated photograph-based outcome instruments designed specifically for assessment of each upper facial area. The MAS for LCL ranged as 0 to 4 where 0 is "No lines", 1 is "Mild lines", 2 is "Moderate lines", 3 is "Severe lines" and 4 is "Very severe lines".

Time frame:
Day 30
Reported as:
Number · percentage of subjects
Main Period: Percentage of Subjects With a Score of 0 (no) or 1 (Mild) on MAS for Both Left and Right LCL at Maximum Contraction as Assessed by the Investigator at Day 30
percentage of subjectsMain Period: Placebo (Group P)Main Period: NT 201 (Group U)
Main Period: Percentage of Subjects With a Score of 0 (no) or 1 (Mild) on MAS for Both Left and Right LCL at Maximum Contraction as Assessed by the Investigator at Day 303.381.3
Statistical analysis
  • Main Period: Placebo (Group P) vs Main Period: NT 201 (Group U) · Mantel Haenszel · p = <0.0001
SecondaryMain Period: Percentage of Subjects With a Score of 0 (no) or 1 (Mild) on MAS for GFL at Maximum Contraction as Assessed by the Subject at Day 30

The MAS are 5-point scales used to identify responders in a clinical context. They are validated photograph-based outcome instruments designed specifically for assessment of each upper facial area. The MAS for GFL ranged as 0 to 4 where 0 is "No glabellar lines", 1 is "Mild glabellar lines", 2 is "Moderate glabellar lines", 3 is "Severe glabellar lines" and 4 is "Very severe glabellar lines".

Time frame:
Day 30
Reported as:
Number · percentage of subjects
Main Period: Percentage of Subjects With a Score of 0 (no) or 1 (Mild) on MAS for GFL at Maximum Contraction as Assessed by the Subject at Day 30
percentage of subjectsMain Period: Placebo (Group P)Main Period: NT 201 (Group U)
Main Period: Percentage of Subjects With a Score of 0 (no) or 1 (Mild) on MAS for GFL at Maximum Contraction as Assessed by the Subject at Day 302.275.6
Statistical analysis
  • Main Period: Placebo (Group P) vs Main Period: NT 201 (Group U) · Mantel Haenszel · p = <0.0001
SecondaryMain Period: Percentage of Subjects With a Score of 0 (no) or 1 (Mild) on MAS for HFL at Maximum Contraction as Assessed by the Subject at Day 30

The MAS are 5-point scales used to identify responders in a clinical context. They are validated photograph-based outcome instruments designed specifically for assessment of each upper facial area. The MAS for HFL ranged as 0 to 4 where 0 is "No lines", 1 is "Mild lines", 2 is "Moderate lines", 3 is "Severe lines" and 4 is "Very severe lines".

Time frame:
Day 30
Reported as:
Number · percentage of subjects
Main Period: Percentage of Subjects With a Score of 0 (no) or 1 (Mild) on MAS for HFL at Maximum Contraction as Assessed by the Subject at Day 30
percentage of subjectsMain Period: Placebo (Group P)Main Period: NT 201 (Group U)
Main Period: Percentage of Subjects With a Score of 0 (no) or 1 (Mild) on MAS for HFL at Maximum Contraction as Assessed by the Subject at Day 301.177.3
Statistical analysis
  • Main Period: Placebo (Group P) vs Main Period: NT 201 (Group U) · Mantel Haenszel · p = <0.0001
SecondaryMain Period: Percentage of Subjects With a Score of 0 (no) or 1 (Mild) on MAS for Both Left and Right LCL at Maximum Contraction as Assessed by the Subject at Day 30

The MAS are 5-point scales used to identify responders in a clinical context. They are validated photograph-based outcome instruments designed specifically for assessment of each upper facial area. The MAS for LCL ranged as 0 to 4 where 0 is "No lines", 1 is "Mild lines", 2 is "Moderate lines", 3 is "Severe lines" and 4 is "Very severe lines".

Time frame:
Day 30
Reported as:
Number · percentage of subjects
Main Period: Percentage of Subjects With a Score of 0 (no) or 1 (Mild) on MAS for Both Left and Right LCL at Maximum Contraction as Assessed by the Subject at Day 30
percentage of subjectsMain Period: Placebo (Group P)Main Period: NT 201 (Group U)
Main Period: Percentage of Subjects With a Score of 0 (no) or 1 (Mild) on MAS for Both Left and Right LCL at Maximum Contraction as Assessed by the Subject at Day 303.365.9
Statistical analysis
  • Main Period: Placebo (Group P) vs Main Period: NT 201 (Group U) · Mantel Haenszel · p = <0.0001
SecondaryMain Period: Global Aesthetic Improvement Scale (GAIS) at Day 30 as Assessed by the Subjects

The GAIS is a 7-point Likert scale capturing the global aesthetic improvement ranging from +3 (very much improved); +2 (much improved); +1 (improved); 0 (no change); -1 (worse); -2 (much worse); -3 (very much worse), as assessed by the subject. GAIS as assessed by the subject at Day 30 was analyzed using an analysis of covariance (ANCOVA) model.

Time frame:
Day 30
Reported as:
Least squares mean · score on a scale
Main Period: Global Aesthetic Improvement Scale (GAIS) at Day 30 as Assessed by the Subjects
score on a scaleMain Period: Placebo (Group P)Main Period: NT 201 (Group U)
Main Period: Global Aesthetic Improvement Scale (GAIS) at Day 30 as Assessed by the Subjects0.08 (-0.06 to 0.23)2.24 (2.14 to 2.35)
Statistical analysis
  • Main Period: Placebo (Group P) vs Main Period: NT 201 (Group U) · ANCOVA · p = <0.0001
SecondaryMain Period: Percentage of Subjects With at Least One-grade Improvement From Baseline to Day 30 on MAS for GFL at Maximum Contraction as Assessed by the Investigator

The MAS are 5-point scales used to identify responders in a clinical context. They are validated photograph-based outcome instruments designed specifically for assessment of each upper facial area. The MAS for GFL ranged as 0 to 4 where 0 is "No glabellar lines", 1 is "Mild glabellar lines", 2 is "Moderate glabellar lines", 3 is "Severe glabellar lines" and 4 is "Very severe glabellar lines".

Time frame:
Day 30
Reported as:
Number · percentage of subjects
Main Period: Percentage of Subjects With at Least One-grade Improvement From Baseline to Day 30 on MAS for GFL at Maximum Contraction as Assessed by the Investigator
percentage of subjectsMain Period: Placebo (Group P)Main Period: NT 201 (Group U)Main Period: NT 201 and Placebo (Group G and H)
Main Period: Percentage of Subjects With at Least One-grade Improvement From Baseline to Day 30 on MAS for GFL at Maximum Contraction as Assessed by the Investigator1.196.596.7
Statistical analysis
  • Main Period: Placebo (Group P) vs Main Period: NT 201 (Group U) · Mantel Haenszel · p = <0.0001
  • Main Period: Placebo (Group P) vs Main Period: NT 201 and Placebo (Group G and H) · Mantel Haenszel · p = <0.0001
SecondaryMain Period: Percentage of Subjects With at Least One-grade Improvement From Baseline to Day 30 on MAS for HFL at Maximum Contraction as Assessed by the Investigator

The MAS are 5-point scales used to identify responders in a clinical context. They are validated photograph-based outcome instruments designed specifically for assessment of each upper facial area. The MAS for HFL ranged as 0 to 4 where 0 is "No lines", 1 is "Mild lines", 2 is "Moderate lines", 3 is "Severe lines" and 4 is "Very severe lines".

Time frame:
Day 30
Reported as:
Number · percentage of subjects
Main Period: Percentage of Subjects With at Least One-grade Improvement From Baseline to Day 30 on MAS for HFL at Maximum Contraction as Assessed by the Investigator
percentage of subjectsMain Period: Placebo (Group P)Main Period: NT 201 (Group U)Main Period: NT 201 and Placebo (Group G and H)
Main Period: Percentage of Subjects With at Least One-grade Improvement From Baseline to Day 30 on MAS for HFL at Maximum Contraction as Assessed by the Investigator2.296.096.7
Statistical analysis
  • Main Period: Placebo (Group P) vs Main Period: NT 201 (Group U) · Mantel Haenszel · p = <0.0001
  • Main Period: Placebo (Group P) vs Main Period: NT 201 and Placebo (Group G and H) · Mantel Haenszel · p = <0.0001
SecondaryMain Period: Percentage of Subjects With at Least One-grade Improvement From Baseline to Day 30 on MAS for Both Left and Right LCL at Maximum Contraction as Assessed by the Investigator

The MAS are 5-point scales used to identify responders in a clinical context. They are validated photograph-based outcome instruments designed specifically for assessment of each upper facial area. The MAS for LCL ranged as 0 to 4 where 0 is "No lines", 1 is "Mild lines", 2 is "Moderate lines", 3 is "Severe lines" and 4 is "Very severe lines".

Time frame:
Day 30
Reported as:
Number · percentage of subjects
Main Period: Percentage of Subjects With at Least One-grade Improvement From Baseline to Day 30 on MAS for Both Left and Right LCL at Maximum Contraction as Assessed by the Investigator
percentage of subjectsMain Period: Placebo (Group P)Main Period: NT 201 (Group U)Main Period: NT 201 and Placebo (Group G and H)
Main Period: Percentage of Subjects With at Least One-grade Improvement From Baseline to Day 30 on MAS for Both Left and Right LCL at Maximum Contraction as Assessed by the Investigator7.989.029.3
Statistical analysis
  • Main Period: Placebo (Group P) vs Main Period: NT 201 (Group U) · Mantel Haenszel · p = <0.0001
SecondaryMain Period: Global Aesthetic Improvement Scale (GAIS) at Day 30 as Assessed by the Investigator

The GAIS is a 7-point Likert scale capturing the global aesthetic improvement ranging from +3 (very much improved); +2 (much improved); +1 (improved); 0 (no change); -1 (worse); -2 (much worse); -3 (very much worse), as assessed by the investigator. GAIS as assessed by the investigator at Day 30 was analyzed using an ANCOVA model.

Time frame:
Day 30
Reported as:
Least squares mean · score on a scale
Main Period: Global Aesthetic Improvement Scale (GAIS) at Day 30 as Assessed by the Investigator
score on a scaleMain Period: Placebo (Group P)Main Period: NT 201 (Group U)Main Period: NT 201 and Placebo (Group G and H)
Main Period: Global Aesthetic Improvement Scale (GAIS) at Day 30 as Assessed by the Investigator0.05 (-0.08 to 0.18)2.43 (2.34 to 2.53)1.99 (1.86 to 2.12)
Statistical analysis
  • Main Period: Placebo (Group P) vs Main Period: NT 201 (Group U) · ANCOVA · p = <0.0001
  • Main Period: Placebo (Group P) vs Main Period: NT 201 and Placebo (Group G and H) · ANCOVA · p = <0.0001
SecondaryMain Period: Number of Subjects With Related Treatment-Emergent Adverse Events (TEAEs)

TEAEs during the Main Period are defined as adverse events (AEs) with onset or worsening on or after date and time of first dose of study treatment and before date and time of first administration of study treatment in the OLEX period or the final study visit, if subject was not treated in the OLEX period. An AE is considered to be related if a causal relationship between study treatment and the AE is at least reasonably possible.

Time frame:
Up to 22 Weeks
Reported as:
Count of participants · Participants
Main Period: Number of Subjects With Related Treatment-Emergent Adverse Events (TEAEs)
ParticipantsMain Period: Placebo (Group P)Main Period: NT 201 (Group U)Main Period: NT 201 and Placebo (Group G and H)
Main Period: Number of Subjects With Related Treatment-Emergent Adverse Events (TEAEs)2116
SecondaryOLEX Period: Number of Subjects With Related TEAEs

TEAEs of the OLEX period are defined as AEs with onset or worsening on or after date and time of first dose of study treatment in the OLEX period up to and including the final study visit. An AE is considered to be related if a causal relationship between study treatment and the AE is at least reasonably possible.

Time frame:
Up to 39 Weeks
Reported as:
Count of participants · Participants
OLEX Period: Number of Subjects With Related TEAEs
ParticipantsOLEX: NT 201 (Main Period: Group P)OLEX: NT 201 (Main Period: Group U)OLEX: NT 201 (Main Period: Group G and H)
OLEX Period: Number of Subjects With Related TEAEs1063

Adverse events

Collected over Main Period: Up to 22 weeks; OLEX Period: Up to 39 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Main Period: Placebo (Group P)0/91 (0%)1/91 (1.1%)10/91 (11%)
Main Period: NT 201 (Group U)0/179 (0%)0/179 (0%)18/179 (10.1%)
Main Period: NT 201 and Placebo (Group G and H)0/92 (0%)1/92 (1.1%)7/92 (7.6%)
OLEX: NT 201 (Main Period: Group P)0/86 (0%)1/86 (1.2%)16/86 (18.6%)
OLEX: NT 201 (Main Period: Group U)0/144 (0%)2/144 (1.4%)15/144 (10.4%)
OLEX: NT 201 (Main Period: Group G and H)0/73 (0%)0/73 (0%)5/73 (6.8%)
Most frequent serious events
Most frequent serious events
EventMain Period: Placebo (Group P)Main Period: NT 201 (Group U)Main Period: NT 201 and Placebo (Group G and H)OLEX: NT 201 (Main Period: Group P)OLEX: NT 201 (Main Period: Group U)OLEX: NT 201 (Main Period: Group G and H)
Myocardial infarctionCardiac disorders0/910/1790/921/860/1440/73
Intraductal proliferative breast lesionNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/910/1790/920/860/1440/73
Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/910/1791/920/861/1440/73
Cerebrovascular accidentNervous system disorders0/910/1790/920/861/1440/73
Most frequent other events
Most frequent other events
EventMain Period: Placebo (Group P)Main Period: NT 201 (Group U)Main Period: NT 201 and Placebo (Group G and H)OLEX: NT 201 (Main Period: Group P)OLEX: NT 201 (Main Period: Group U)OLEX: NT 201 (Main Period: Group G and H)
Injection site bruisingGeneral disorders2/914/1794/927/864/1443/73
COVID-19Infections and infestations3/918/1792/926/865/1442/73
Blood pressure increasedInvestigations5/916/1792/925/868/1440/73

Baseline characteristics

The full analysis set (FAS) included all randomized subjects.

Age, Continuous
Age, Continuous(years)Main Period: Placebo (Group P)Main Period: NT 201 (Group U)Main Period: NT 201 and Placebo (Group G and H)Total
Mean47.5 ± 12.9947.2 ± 13.2147.8 ± 13.4747.4 ± 13.19
Sex: Female, Male
Sex: Female, Male(Participants)Main Period: Placebo (Group P)Main Period: NT 201 (Group U)Main Period: NT 201 and Placebo (Group G and H)Total
Female7915475308
Male12251754
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Main Period: Placebo (Group P)Main Period: NT 201 (Group U)Main Period: NT 201 and Placebo (Group G and H)Total
Hispanic or Latino284929106
Not Hispanic or Latino6313063256
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Main Period: Placebo (Group P)Main Period: NT 201 (Group U)Main Period: NT 201 and Placebo (Group G and H)Total
American Indian or Alaska Native1001
Asian27312
Native Hawaiian or Other Pacific Islander0000
Black or African American720734
White7915080309
More than one race2226
Unknown or Not Reported0000
08

Study locations

12 sites
  • Merz Investigational Site
    Encino, California 91436, United States
  • Merz Investigational Site
    Newport Beach, California 92663, United States
  • Merz Investigational Site
    San Diego, California 92121, United States
  • Merz Investigational Site
    Greenwood Village, Colorado 80111, United States
  • Merz Investigational Site
    Washington, District of Columbia 20037, United States
  • Merz Investigational Site
    Aventura, Florida 33180, United States
  • Merz Investigational Site
    Boca Raton, Florida 33431, United States
  • Merz Investigational Site
    Metairie, Louisiana 70006, United States
  • Merz Investigational Site
    New York, New York 10028, United States
  • Merz Investigational Site
    New York, New York 10065, United States
  • Merz Investigational Site
    New York, New York 10075, United States
  • Merz Investigational Site
    Nashville, Tennessee 37215, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2020 to primary completion in Apr 2021, 6 months.

Results were first posted in May 2024, 3 years after primary completion. A results delay was requested in Apr 2022.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 13, 2020
First posted
Oct 20, 2020
StartActual
Sep 23, 2020
Primary completionActual
Apr 15, 2021
CompletionActual
May 9, 2022
Results delay requested
Apr 12, 2022
Results first posted
May 8, 2024
Last update
May 8, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04594213
Responsible party
Sponsor
First posted
Oct 20, 2020
Start date
Sep 23, 2020
Primary completion
Apr 15, 2021
Completion
May 9, 2022
Results posted
May 8, 2024
Last update
May 8, 2024

Study contacts

Merz Medical Expert
study director · Merz North America, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: incobotulinumtoxinA

Start the discussion